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disease-specific measure has been described in the litera-
ture, the CLAU-S, but this is designed for use in patients
with claudication only. Currently, there is no disease-spe-
cific QOL instrument for use in all patients with lower
limb ischemia.9
In this study, established methods have been used to
develop a disease-specific QOL instrument for studies
involving patients with lower limb ischemia (Fig 1). The
King’s College Hospital’s Vascular Quality of Life
Questionnaire (VascuQol) has been designed to be an
evaluative measure and sensitive to within-patient change.
PATIENTS AND METHODS
Stage I: item selection, item reduction, formulating,
and pretesting the questionnaire
Item selection. Items were identified with the opin-
ions of two consultants in vascular surgery, a consultant in
rehabilitation medicine, a diabetic foot specialist, a public
health consultant, a vascular nurse, and a senior physio-
therapist before a focus group of five “expert patients”
with lower limb ischemia (3 with claudication and 2 with
rest pain, one of whom had ischemic ulcers) was con-
vened. A semistructured tape-recorded interview identi-
fied additional QOL issues for inclusion in the item list.
This approach and the use of a small number of articulate
Quality of life (QOL) is emerging as an important
outcome measure for interventions designed to improve
health, well-being, or both. In the assessment of patients
with lower limb ischemia, the end points of ankle/brachial
pressure index (ABPI), walking distance, amputation, and
death have only recently been augmented by QOL mea-
sures. Over recent years, a wide variety of different instru-
ments have been used.1,2 These range from hospital-
devised scales to internationally recognized generic mea-
sures such as the Short-Form 36 (SF-36),3,4 the
Nottingham Health Profile,5 and the Sickness Impact
Profile.6 Recently, authors have suggested that the SF-36
be used as a standard instrument in vascular studies,7
although it has been recommended that this should 
be accompanied by a disease-specific measure.8 Another
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Aims: The purpose of this study was to develop and validate an easily used disease-specific quality of life (QOL) mea-
sure for patients with chronic lower limb ischemia and to design an evaluative instrument, responsive to within-
subject change, that adds to clinical measures of outcome when comparing treatment options in the management of
lower limb ischemia.
Methods: The first phase consisted of item generation, item reduction, formulating, and pretesting in patients with
ischemia. The proportion of patients who selected an item as troublesome and the mean importance they attached to
it were combined to give a clinical impact factor. Items with the highest clinical impact factor were used to formulate
a new 25-item questionnaire that was then pretested in 20 patients with lower limb ischemia. In the second phase, reli-
ability, validity, and responsiveness of the new questionnaire were assessed in 39 patients with lower limb ischemia who
were tested at 0 and 4 weeks. The King’s College Hospital’s Vascular Quality of Life Questionnaire and the Short-Form
36 were administered at each visit, and treadmill walking distance and ankle/brachial pressure indices were recorded.
The new questionnaire’s reliability, internal consistency, responsiveness, and validity were determined.
Results: Areas of QOL impairment were consistent through the ranges of disease severity and age, with no apparent dif-
ferences between the men and women. Therefore, a single questionnaire is applicable to all patients with chronic lower
limb ischemia. In stable patients test-retest scores demonstrated a reliability of r more than 0.90. Each item had inter-
nal consistency (item-domain Cronbach α = .7-.9). The questionnaire was responsive to change, with correlation
between change in the questionnaire’s total score and both global and clinical indicators of change (P < .001). The
questionnaire showed face and construct validity.
Conclusions: This disease-specific questionnaire is reliable, responsive, valid, and ready for use as an outcome measure
in clinical trials. It is sensitive to the concerns of patients with lower limb ischemia, offering a simple method to mea-
sure the effect of interventions on their QOL. (J Vasc Surg 2001;33:679-87.)
patients judged to have good insight into their condition
have been successfully used in the development of other
disease-specific scales.10,11 A review was conducted of
existing generic measures that have been used in vascular
trials (eg, the SF-36, the Nottingham Health Profile, the
Sickness Impact Profile, and the Spitzer QL-index)3-8,12
and disease-specific questionnaires developed for asthma13
and dyspepsia14 with the aim of ensuring that the item list
was comprehensive. Thus, a list of 89 items thought to be
of most concern to patients with lower limb ischemia was
compiled. Additional items identified by the patient group
were in the emotional and activity domains, with their dis-
ease causing frustration, fear of becoming housebound,
increased cost of living, difficulty using public transport,
and limitation exercising or playing with pets.
Item reduction. A total of 137 patients with lower
limb ischemia (Fontaine stages II-IV) were recruited
from three hospitals in the Southeast Thames region
(King’s College, Guy’s, and Lewisham). They were asked
to participate in the study as they attended the vascular
outpatient’s departments between January 1998 and
April 1998 if they were not confused and had an adequate
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Fig 1. Summary of Questionnaire Development
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Fig 2. Change in test score versus change in treadmill distance.
Fig 3. Change in test score versus change in ABPI.
knowledge of English. The same interviewer saw each
patient.
By means of a structured interview, each item’s fre-
quency was defined as the proportion of patients who indi-
cated an item as having troubled them in the last year. This
was recorded on a five-point scale from “not important” to
“extremely important,” allowing the calculation of the mean
importance for each item. The product of the frequency and
mean importance is termed the clinical impact factor (CIF),
and the range of scores was 0 to 5. If all 137 patients rated
an item of maximal importance, the CIF would be 5.0; if
they all rated it of no importance, it would be 0.
Formulating the questionnaire. Items were then
ranked in descending order of the CIF to enable compari-
son with respect to sex, Fontaine classification, diabetes,
treadmill walking distances, and ABPI. The highest-ranking
items, affecting 40% or more of the population of this
study, were included in the questionnaire with one excep-
tion: gardening, which was excluded because it was not
easily translatable between urban and rural settings or
among nations. In the final questionnaire, negatively
worded items were avoided, seven-point response options
were used, and for items addressing either pain or symp-
toms, both the leg and the foot were referred to in each
stem statement.
With regard to pain when walking, we thought that
the questionnaire should be able to distinguish between
how often this symptom occurred and the severity of the
pain when it did arise. Items assessing pain were allocated
a domain distinct from other symptoms, as is standard in
the QOL measures reviewed. 
Because of previously reported unreliability in estimat-
ing walking distance,15 we chose not to incorporate
absolute measures of distance in the items, and instead,
patients graded the change in their walking distance from
“a very great deal worse” through “a very great deal bet-
ter.” The final 25-item questionnaire was subdivided into
five domains: pain (4 items), symptoms (4 items), activi-
ties (8 items), social (2 items), and emotional (7 items).
Pretesting the questionnaire. To eliminate ambigui-
ties and ensure that the questionnaire was easily under-
stood, we selected 10 patients with lower limb ischemia at
random from King’s College Hospital’s vascular outpa-
tient department. After their comments, minor modifica-
tions were made: this related to altering the instructions
on the front sheet (providing an example question) and to
changing the wording of the walking distance item.
Previously, the terms increased and decreased were used in
the stem of items 9 and 24. These terms were not differ-
entiated from each other by two patients and were there-
fore changed to improved and has become less to provide a
definite distinction between the two. Another 10 patients
completed the new questionnaire, and no further modifi-
cations were suggested.
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Fig 4. Change in test score versus change in overall symptoms.
Stage II: evaluating reliability, validity, and respon-
siveness
Over a period of 3 months, 43 patients attending the
vascular clinic at King’s College Hospital with lower limb
ischemia (Fontaine stages II-IV = Rutherford grades 0 cat-
egory 1 and I–III) were recruited for evaluation of the
questionnaire, if they were able to reattend at 4 weeks.
They were excluded if they were confused or had an inad-
equate knowledge of English. Four patients failed to reat-
tend for the 4-week appointment. On each occasion the
King’s College Hospital VascuQol was administered
alongside the SF-36 questionnaire. Treadmill walking dis-
tances were measured, and resting ABPIs were calculated.
At the second visit each patient indicated on an additional
15-point scale whether they considered their overall symp-
toms in their legs to have changed (scoring from –7 = a
very great deal worse, through 0 = no change, to 7 = a
very great deal better). 
Reliability. Test-retest scores were compared in those
who had experienced little change in their walking dis-
tance, overall symptom change, and ABPIs. An intraclass
correlation coefficient was calculated (reliability coeffi-
cient), and Cronbach α was used to determine the inter-
nal consistency of the questionnaire.16
Construct validity. A priori predictions of the King’s
College Hospital’s VascuQol performance were examined
in relation to both clinical measures of lower limb ischemia
and “like” domains measured by the SF-36.
For validation of the discriminative properties of the
VascuQol (cross-sectional construct validity), if the instru-
ment were valid, there would be a moderate correlation
between disease severity (Fontaine classification and tread-
mill walking distance) and total questionnaire score.
Similarly the activities, pain, and emotional, domains in
the King’s College Hospital’s VascuQol should correlate
with the physical, pain, and the mental health domains in
the SF-36.
With regard to the evaluative properties of the
VascuQol (longitudinal construct validity), we predicted
correlation between change in the VascuQol score and
change in the walking distance. This correlation was one
of the measures of responsiveness.
Responsiveness. The responsiveness of the King’s
College Hospital’s VascuQol and the SF-36 domain scores
were compared by observing the change in the King’s
College Hospital’s VascuQol total score with other indices
of change (treadmill walking distance, patient’s global esti-
mate of change in their symptoms, and change in ABPIs).
RESULTS
The characteristics of the 137 patients analyzed in
Stage I and the 39 patients analyzed in Stage II are shown
in Table I.
Stage I. Over a period of 4 months 137 patients
entered the study. On direct questioning of the patients at
this stage, no new items emerged that had not been
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included in the process of item selection. In each patient
subgroup for Fontaine classification, for diabetic status,
for sex, and for ABPI and walking distance (available in
102 of the 137 patients), the item ranking by CIF was
consistent, so a single questionnaire was synthesized that
was applicable to patients with lower limb ischemia in all
subgroups. Table II shows some of the CIF data and rank-
ing within the emotional domain. 
The CIF tended to be higher in patients with more
severe disease: mean CIF scores for all the items signifi-
cantly increased from Fontaine classification II to IV
(Society for Vascular Surgery/International Society for
Cardiovascular Surgery categories 1-6) (P < .003) and in
those able to walk more than 100 m compared with those
walking less than 100 m (P < .02) (Table III).
Stage II. Subsequently, 43 patients seen in the King’s
College Hospital’s vascular clinic with lower limb ischemia
were enrolled for test-retest evaluation of the question-
naire. Four patients failed to attend at 4 weeks, so they
were excluded from the final analysis of results.
Test-retest reliability. At the 4-week follow-up, 17
patients experienced no change in disease status (tread-
mill walking distances changed < 20 m, symptoms
unchanged on the global question or change in ABPI
was < 0.05). The intraclass (reliability) coefficient for
this group’s test-retest scores was 0.94 (P < .001, CI >
90%). Item-total score Cronbach α values exceeded .90.
The item-domain score α values were all between .7 and
.8, levels falling within parameters suggested as optimal
for item inclusion within a questionnaire17 and indica-
tive good internal consistency.
Construct validity. Table IV shows the correlations
relating to the cross-sectional construct (ie, discrimina-
tive properties) of the questionnaire. The King’s College
Hospital’s VascuQol total score had a correlation with
the Fontaine classification of disease severity of r = –0.79
(P < .001) and with treadmill walking distances of r =
0.36 (P < .05).
The pain and the activities domains had correlations
with the pain and the physical domains in the SF-36 of r
Table I. Patient characteristics
Characteristic Stage I Stage II
Median age (y) (interquartile range) 69 (53-77) 67 (39-83)
Sex
Male 96 24
Female 41 15
Fontaine classification
II 70 18
III 36 14
IV 31 7
Walking distance < 100 m 54 16
ABPI < 0.65 51 5
Diabetic 39 7
Values are numbers of subjects unless otherwise stated.
= 0.69 (P < .001) and r = .65 (P < .001), respectively. The
King’s College Hospital’s VascuQol emotional domain
correlated with the SF-36 mental health domain at r =
0.45, (P < .05).
The longitudinal construct validity, relating to the
evaluative properties of the questionnaire, was confirmed.
The correlation between change in the King’s College
Hospital’s VascuQol score and change in walking distance
was 0.57 (P < .001) (Fig 1).
Content validity. This had been established in Stage
I of the questionnaire’s development, identifying the items
that are important in having an impact on QOL in patients
with lower limb ischemia.
Responsiveness. As well as the 17 stable patients
(44%), 6 patients improved after intervention (4 angio-
plasty, and 2 bypass grafts) (15%), 7 patients deteriorated
(18%), and 9 improved without intervention (23%). The
individual patient’s change in VascuQol scores and change
in the clinical indices are shown as scatter-plot Figs 2 to 4.
The correlations between change in King’s College
Hospital’s VascuQol and SF-36 scores and change in the
clinical indices (treadmill walking distances, ABPIs) and
symptoms are shown in Table V. The changes in the
King’s College Hospital’s VascuQol total and each of the
domain scores were statistically significantly correlated
with the change in treadmill walking distances and global
estimate of change in the symptoms of lower limb
ischemia, apart from the symptom domain, which did not
correlate with the change in walking distances.
The SF-36 was responsive in only three of its eight
domains. The role physical domain correlated with change
in symptoms alone; the physical function and pain
domains correlated with change in symptoms and walking
distance (P < .05). Change in the ABPI did not correlate
with a change in the total King’s College Hospital’s
VascuQol score or with domain scores in the King’s
College Hospital’s VascuQol or SF-36 (Fig 2).
DISCUSSION
The most important consideration when recommend-
ing a QOL scale for use internationally in vascular clinical
trials is that it should detect those components of QOL
relevant to vascular disease,9 and be sensitive to the impact
that peripheral vascular disease has on these. This calls for
a disease-specific scale; a generic instrument does not meet
this standard. Accepted wisdom in other fields is that
generic measures will always require supplementation with
disease-specific measures to detect important clinical
change.10 In 1993 in the British Medical Journal, Garratt
et al8 advocated the SF-36 for use as an outcome measure
in the National Health Service, although they emphasized
that it should be used in combination with a disease-
specific measure.
In the process of formulating the King’s College
Hospital’s VascuQol questions, it was taken into account
that negatively worded items tend to have lower validity
coefficients.18 Subjects find difficulty discriminating beyond
seven levels, and having seven categories of response com-
pared with five increases reliability by about 12%.17
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Table II. Emotional CIF scores by Fontaine classification of disease severity
Fontaine classification
II III IV
Rank CIF Rank CIF Rank CIF
Emotions
Frustration with physical limitations 1 2.98 1 3.25 1 3.69
Fear of loss of limb 2 1.70 2 2.44 2 3.15
Anxiety about peripheral vascular disease 3 1.61 3 2.32 4 2.42
Worry about becoming housebound 4 1.35 4 2.08 5 2.32
Worry about injuring the leg 7 1.03 6 1.81 3 2.53
Guilt about relying on others 6 1.19 5 1.91 7 1.80
Depression 10 0.67 7 1.64 6 1.91
Fear of surgery 5 1.31 9 1.31 11 1.39
N = 137 patients.
Table III. Increasing mean CIF scores with increasing
disease severity 
Fontaine SVS/ISCVS Mean CIF
classification categories of all items
II 1–31 0.99
III 4 1.36
IV 5 and 6 1.45*
Walking Mean CIF
distance (m) of all items
< 100 1.37
> 100 1.07†
N = 102 patients.
*P < .003.
†P < .02 (probability that there is no difference in the mean CIF for dif-
ferent levels of the contrast variable).
CIF, Clinical impact factor; ISCVS, International Society for
Cardiovascular Surgery; SVS, Society for Vascular Surgery.
In previous studies of patients with lower limb
ischemia, the emotional domain has been poorly reliable
in this group7 and found not to improve after successful
treatment.4 However, the emotional domain in the King’s
College Hospital’s VascuQol is likely to prove a useful
evaluative measure by covering concerns of patients with
lower limb ischemia that generic measures do not.
A weighting system was not applied to the King’s
College Hospital’s VascuQol questionnaire. The intention
was that this instrument should be responsive to within
subject change and each domain capable of being analyzed
separately, so weighting was not so important.13
Weighting also may increase the complexity in scoring of
a questionnaire, while adding little to the performance of
the instrument.19
A high level of internal consistency is desirable when
scores are used to compare individuals (Cronbach α coef-
ficient of > .95 is recommended).20 It is less important
when comparing groups of patients (when α coefficients
of between .7 and .9 are optimal) and higher coefficients
can be due to redundant items.17 Because the King’s
College Hospital’s VascuQol domains may be individually
scored, the within-domain internal consistency was
thought to be of prime importance, and the item-domain
Cronbach α scores were all between .7 and .9.
For the King’s College Hospital’s VascuQol high con-
tent validity to be maintained, 25 items were considered
the fewest allowable. Patients found the King’s College
Hospital’s VascuQol easy to complete, and the mean time
taken to complete the questionnaire was 9.6 minutes.
Validity is the most important attribute of any measure
of QOL: it must measure what it is supposed to measure.
However, a gold standard against which the King’s
College Hospital’s VascuQol may be compared does not
exist. Construct validity requires that several predictions
were made with regard to the way in which the question-
naire would perform against clinical parameters and the
SF-36. The SF-36 was chosen for comparison not only
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because it is a generic QOL measure that has been vali-
dated in its own right, but because within vascular surgery
it has been put forward as the standard measure that
should be used in clinical trials.7,9
Cross-sectional construct validity from data collected
at the first visit was shown, with correlation between
domains in the King’s College Hospital’s VascuQol and
SF-36 domains. This form of validity relates to the dis-
criminative qualities of the questionnaire (ie, the ability of
the questionnaire to differentiate between patients with
differing disease severity). Although this is an attribute fre-
quently tested when QOL instruments are used, evaluative
properties are of greater relevance when measuring clinical
outcome. This refers to the ability of an instrument to
detect small yet clinically significant within-patient change.
The responsiveness of the King’s College Hospital
VascuQol was demonstrated by the high correlation between
change in total and domain scores, change in treadmill walk-
ing distances, and the patient’s global rating of change in
their symptoms. Most patients in the second phase of the
study had been managed conservatively in the outpatient set-
ting with advice on regular daily exercise, to the onset and, if
possible, through their claudication distance, stopping smok-
ing, and took aspirin daily, as well as undergoing investigation
and treatment where required of other risk factors. Although
four patients had been treated with angioplasty and there
were two infrainguinal bypass grafts, the purpose of this study
was not to compare treatment options. Validation of the
King’s College Hospital’s VascuQol’s ability to respond to
change was supported by the fact that the SF-36 performed
as expected: only the SF-36 domains of physical function,
role-physical, and pain showed significant correlation with
change in walking distance and global rating of symptoms.
This corresponds with the performance of the SF-36 in a
study by Currie et al,4 who looked at the impact of treating
intermittent claudication on QOL. 
Change in the ABPI correlated poorly with change in
QOL scores of both the King’s College Hospital’s
Table IV. Cross-sectional construct validity
VascuQol
Total score Pain Activities Symptoms Emotional Social
Fontaine classification –0.79* –0.68* –0.77* –0.63* –0.75* –0.74*
Walking distance 0.36† 0.27 0.27 0.32† 0.39† 0.38†
ABPI 0.30 0.27 0.29 0.16 0.32† 0.24
SF-36 domains
Physical function — 0.69* 0.69* 0.41† 0.64* 0.55*
Role-physical — 0.56* 0.56* 0.32* 0.53* 0.43†
Role-emotional — 0.68* 0.59* 0.40* 0.66* 0.60*
Social function — 0.64* 0.66* 0.50* 0.69* 0.62*
Pain — 0.61* 0.58* 0.44† 0.55* 0.41†
Mental health — 0.35† 0.29 0.20 0.45† 0.28
Energy — 0.57* 0.55* 0.35† 0.48† 0.45†
Health perception — 0.38† 0.27 0.28 0.39 0.23
Spearman rank correlation coefficient.
*P < .001. 
†P < .05.
VascuQol and SF-36. Lack of correlation between the
ABPI and QOL measures has been noted in previous stud-
ies.4,21 This highlights the problem that a frequently used
hard measure of outcome does not necessarily reflect
change in a patient’s perceived QOL.
Another disease-specific QOL questionnaire for
patients with lower limb ischemia has been reported in the
literature. The CLAU-S measure was designed in
Germany as a disease-specific measure in patients whose
disease severity was graded as Fontaine II. The question-
naire content, however, reflects its use as part of a post-
marketing surveillance study of naftidrofuryl treatment of
peripheral vascular disease with a domain evaluating this
drug’s side effect profile. Validation data concentrated on
their discriminative rather than evaluative properties, and
with more than 60 items it is too long for routine use.
The Walking Impairment Questionnaire23 is a well-
validated, disease-specific functional scale for use in
patients with claudication that has been used as an adjunct
to generic QOL measures. The Walking Impairment
Questionnaire is not in itself a QOL life measure.
It might be asked that because clinical trials rarely
evaluate claudication together with critical ischemia, why
generate a single questionnaire? Also, can a single ques-
tionnaire suffice for evaluation of the wide variance in
symptoms associated with peripheral vascular disease? We
think that a single questionnaire that encompasses the
range of disease severity in peripheral vascular disease is
desirable for several reasons. First, a single questionnaire
that would apply to diseases ranging from claudication to
critical ischemia provides the ability to follow up patients
with the same scale as their disease deteriorates or
improves. In the context of clinical trials, although the
initial inclusion of patients may be restricted to a sub-
group of patients with peripheral vascular disease, one
would hope that after intervention, each patient’s disease
severity grading would change. If a patient became down-
graded in terms of disease severity, a scale would be of lit-
tle use if it could not respond to this. A too specific scale
would require a separate instrument for the patient who
had changed from having rest pain to claudication alone,
and using separate scales would not enable comparison.
Second, a separate questionnaire for each level of disease
severity would be little more than a surrogate for the
established clinical measures and grading, with “floor” or
“ceiling” effects at or near the boundary of each severity
level. Finally, items will be interpreted by patients in rela-
tion to their own disease. Thus, the wide variance in
symptoms associated with peripheral vascular disease can
be accommodated. For example, a patient with claudica-
tion alone would score an inability to take part in social
activities in relation to this symptom. Patients with
ischemic ulcers would consider the symptom components
of their more severe disease when answering this item (eg,
social isolation may in part be due to the need for daily
nursing of the ulcer).
In summary the King’s College Hospital’s VascuQol is
a disease-specific measure of QOL specifically developed
for use in patients with lower limb ischemia. This prelimi-
nary study has shown it to be reliable, valid, and responsive
to within-patient change, and it fulfills the requirements of
an evaluative and a discriminative measure. It satisfies the
recommendation that when the SF-36 is used, a disease-
specific measure should also be administered.24 This is per-
haps particularly true in studies of peripheral vascular
disease where the SF-36 tends to behave as a functional
scale responding best within its physical domains. Concern
has been expressed about how well the SF-36 performs as
a self-administered questionnaire in elderly populations
because of poor rates of completion.25,26
The King’s College Hospital’s VascuQol has been trans-
lated into US English, Canadian French and English, French,
German, Italian, and Swedish, a process that has included
formal linguistic validation (Appendix, online only).
The King’s College Hospital’s VascuQol follows a
well-worn path in disease-specific QOL measure develop-
ment. As with other measures, validity will grow with use,
and further evaluation of responsiveness is required in the
setting of a clinical trial. It is currently being used, along-
side the SF-36, in a multicenter UK trial of bypass graft
versus angioplasty in severe limb ischemia.
Until now there has not been a suitable disease-
specific QOL measure for use in vascular trials. We hope
that other researchers, when measuring QOL as an out-
come in trials of peripheral vascular disease management,
will adopt the King’s College Hospital’s VascuQol.
JOURNAL OF VASCULAR SURGERY
686 Morgan et al April 2001
Table V. Responsiveness of the King’s College Hospital’s VascuQol and the SF-36
King’s College Hospital’s VascuQol
∆Total score ∆Pain ∆Activities ∆Symptoms ∆Emotional ∆Social
∆Global symptoms –0.85* 0.74* 0.75* 0.45† 0.67* 0.56*
∆Walking distance 0.57* 0.41† 0.59* 0.09 0.57* 0.41*
∆ABPI 0.22 0.10 0.28 0.10 0.29 0.18
Correlation of the change (∆) in scores with the global estimates of symptom change, with change in walking distance, and change in ABPIs.
Spearman rank correlation coefficient.
*P < .001.
†P < .05.
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SF-36
∆Physical ∆Social ∆Health
function ∆Role-physical ∆Role-emotional function ∆Pain ∆Mental health ∆Energy perception
0.33† 0.28† –0.15 0.17 0.49† 0.23 0.29 0.12
0.40† 0.20 –0.05 0.07 0.40† 0.24 0.15 0.10
0.10 –0.06 –0.11 –0.13 –0.11 –0.11 –0.23 –0.08
